Suzanne Hamel
- T. 617.439.2160
- F. 617.310.9000
- E. suzanne.hamel@nutter.com
- Download full bio
Overview
Suzanne Hamel is a partner in Nutter’s Corporate and Transactions Department. Her practice is transaction-focused, with a particular focus on life sciences and biotechnology companies. She represents emerging companies, venture capital funds, individual investors, and strategic investors. Whether representing a company or an investor, or a buyer or seller, clients count on Suzanne to guide them through and close their transactions. Many clients return to Suzanne for each financing, transaction, and exit as they grow, and she regularly helps new companies and investors with their first transaction.
Suzanne advises emerging companies and investors on venture capital and private equity financings, including bridge financings and SAFEs, debt financings, secondary sales of stock, and stock transfers to trusts. She also represents venture capital funds, individual investors, and nonprofits in their investments in funds and portfolio companies. Her transactional experience includes mergers and acquisitions, sales of assets, joint ventures, and private placements, and she regularly negotiates distribution and other commercial agreements. She also advises on executive compensation and related employment and intellectual property agreements. Suzanne serves as outside general counsel to emerging companies and other clients as they grow, providing day-to-day counsel on corporate matters.
Notable Experience and Client Impact
- Represented Ticket Evolution Inc., an end-to-end software provider for the event ticketing industry, in connection with its acquisition by Clearlake Capital Group, L.P. and Clearlake operating advisor Sam Soni.
- Represented an e-commerce company in its $25 million Series A financing by a venture capital firm.
- Represented a venture capital fund in a $42 million Series A financing of a biotech company focused on developing precision therapeutics.
- Represented a venture capital fund in a $70 million Series A financing of a gene therapy company.
- Represented a venture capital fund in a $100 million Series A financing of a company focusing on early detection of cancer.
- Represented a venture capital fund in a $30 million Series A financing of a company developing therapies designed to treat severe genetic diseases.
- Represented a venture capital fund in a $133 million Series E financing of a company developing programs focusing on dementia.
- Represented a venture capital fund in $24 million Series B financing of a global fertility benefits company.
- Represented a venture capital fund in a $110 million Series A financing of a biotechnology company developing new treatment options for therapy neurodegenerative diseases.
- Represented a ticket software company in the sale of substantially all of its assets to a ticket marketplace company.
- Represented an early stage company developing Covid tests in a bridge financing.
- Represented an individual investor in various early stage investments.
- Represented a health care business in a $37 million sale to a private equity firm.
- Represented a veterinary business in a $35 million sale to a private equity firm.
- Represented a leading live event ticket B2B exchange company in a combination with a professional ticket seller platform company and purchase of assets of various ticket software applications.
Suzanne has extensive experience advising clients in the following industries:
- Life sciences
- Medical devices and diagnostics
- Technology, Internet, and e-commerce
- Tickets and events
Prior to joining Nutter, Suzanne was an attorney at a Boston-based corporate boutique law firm. Before that, she was an associate at two international law firms. She has also served as outside general counsel to BioSystem Solutions, Inc. and Ticket Technology Holding Company, L.L.C.
During law school, Suzanne was a member of Law Review, a research assistant and named a Dean’s Fellow. Additionally, she interned for the Honorable David S. Tatel of the U.S. Court of Appeals District of Columbia Circuit and at the U.S. Equal Employment Opportunity Commission (EEOC).
Read More
Experience
Experience
News & Insights
News
Honors
Honors
- Chambers USA, Leading U.S. Private Equity: Venture Capital Investment Attorney, 2025-2026
- Legal 500, Boston City Elite, 2026
- The Best Lawyers in America, 2023-2027
- The 2027 Lawdragon 500 Leading Dealmakers in America
- Massachusetts Lawyers Weekly, “2026 Top Women of Law”
Education & Admissions
Education
George Washington University School of Law, J.D.
Lesley College, B.S., magna cum laude
Admissions
- Maryland
- Massachusetts
- Washington, D.C.
Practices
Noteworthy
- Chambers USA, Leading U.S. Private Equity: Venture Capital Investment Attorney, 2025-2026
- Legal 500, Boston City Elite, 2026
- The Best Lawyers in America, 2023-2027
- The 2027 Lawdragon 500 Leading Dealmakers in America
- Massachusetts Lawyers Weekly, “2026 Top Women of Law”